

April 21, 2025

To,
The Chief General Manager
Listing Operation,
BSE Limited,
20th Floor, P. J. Towers,
Dalal Street,
Mumbai – 400 001.
Scrip Code: 524743

Dear Sir/ Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Audit Committee, that met today (21.04.2025), pursuant to the powers delegated to it by the Board has considered and approved the Investment in the Equity shares of the Companies as stated in Annexure I and II.

The details as required under SEBI Listing Regulations, 2015 read with SEBI Circular No. CIR / CFD / CMD / 4/2015 dated 9th September 2015 are given in **Annexure I and II**.

This is for the information of the exchange and the members.

Thanking you,

Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**
(Formerly known as Fischer Chemic Limited)



ARAVINDKUMAR V
COMPANY SECRETARY AND COMPLIANCE OFFICER

ANNEXURE I

Sr. no.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Fischer Hospitality Sdn. Bhd Turnover: Not applicable since the Company was incorporated in FY 2024-2025
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".	Fischer Hospitality Sdn. Bhd will become a foreign subsidiary of the Company. Accordingly, Fischer Hospitality Sdn. Bhd is a related party.
3	Industry to which the entity acquired belongs	Investment Holding
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Not Applicable.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable.
6	Indicative time period for completion of the acquisition.	Not Applicable.
7	Nature of consideration - whether cash consideration or share swap and details of the same.	Cash.
8	Cost of acquisition or the price at which the shares are acquired.	USD 1 Million.

Sr. no.	Particulars	Details
9	Percentage of shareholding/ control acquired and/ or number of shares acquired.	60%
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	Not Applicable since it is a newly incorporated Company.



ANNEXURE II

Sr. no.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Obelabs Inc. Turnover of latest Financial Year: USD 1.6 Million
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".	No
3	Industry to which the entity acquired belongs	Manufacture of other medical and surgical equipment and orthopedic appliances
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Not Applicable.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable.
6	Indicative time period for completion of the acquisition.	Not Applicable.
7	Nature of consideration - whether cash consideration or share swap and details of the same.	Cash.
8	Cost of acquisition or the price at which the shares are acquired.	USD 0.5 Million.

Sr. no.	Particulars	Details
9	Percentage of shareholding/ control acquired and/ or number of shares acquired.	1.70%
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	<p>M/s. Obelab Inc. is a Korean medical device company with the world's first dedicated and miniaturized NIRS (Near-Infrared Spectroscopy) ASICs (Application-Specific Integrated Circuits) for the detection of various neuropsychiatric diseases, powered by AI. Obelab has a strong product portfolio in mental health diagnosis, including for depression and bipolar disorders. This has strong synergies with FMV's health screening business unit. Besides mental health, Obelab has an emerging product portfolio in cerebral oxygen monitoring in ICUs and Operating Theatres, which can be readily sold across FMV's distribution networks.</p> <p>Obelab (HQ: Seoul, Korea, FY24 USD1.6m revenues) is a medical device company that measures blood oxygenation and perfusion levels in the brain to diagnose various mental health and neurological conditions. Obelab's brain imaging devices uses Functional Near Infrared Spectroscopy (fNIRS) technology to measure light absorption in oxygenated / de-oxygenated haemoglobin.</p> <p>FMV will become Obelab's exclusive distributor in India, ASEAN, Africa, and the member countries of the Gulf Cooperation Council, and non-exclusive distributor in all other countries.</p>
